Do urinary mycotoxins or neural antibodies prove a cause of dementia?

Mycotoxins and neural autoantibodies can be biologically relevant findings, but their clinical meaning differs sharply from proof of causation in dementia—particularly in an older adult, in whom common neurodegenerative and systemic causes also require consideration.

Mechanistic evidence

• Specific mycotoxins have plausible neurotoxic mechanisms in experimental systems. Ochratoxin A is associated with oxidative stress, mitochondrial impairment, and an M1-like microglial response; aflatoxin B1 activates human microglia and astrocytes in vitro, and deoxynivalenol can activate NF-κB at sublethal concentrations.
• These findings establish a capacity for certain toxins to promote oxidative and neuroinflammatory signaling, not that ordinary dietary, occupational, or indoor-environment exposures cause neuroinflammation, neurodegeneration, or dementia in humans.
• Human observational studies have associated measured serum or urinary mycotoxins with oxidative-stress markers such as malondialdehyde and 8-OHdG, but cannot establish direction or causality.

Interpretation of test results

• Urinary mycotoxins generally reflect recent exposure—often dietary—with clearance commonly occurring over hours to days. They do not identify the source, establish brain exposure or dose, or predict dementia. Commercial urine testing lacks validated disease-predictive thresholds and healthy reference ranges for attributing chronic neurologic illness.
• Neural autoantibodies demonstrate antigen-specific immune reactivity, but their diagnostic weight depends on phenotype and testing context. Paired serum/CSF testing, appropriate assay confirmation, MRI, EEG, and CSF inflammatory findings are important; CSF is particularly relevant for NMDAR antibodies, while serum may be more sensitive for LGI1/CASPR2.
• Low-titer, serum-only, or phenotype-discordant results can be incidental or false positive, especially in slowly progressive dementia.

Bottom line

• Neither urinary mycotoxin detection nor neural-antibody positivity alone establishes that it is causing dementia. Mycotoxin findings are chiefly exposure/mechanistic signals; antibodies can support immune-mediated disease only when a compatible, usually subacute neurologic syndrome and corroborating investigations are present.